Evogene Ltd. (EVGN) is the 287th largest of 300 AI Platforms companies by market capitalisation, at 3.80 Mn, behind Quantum Genesis AI Corp. at 3.90 Mn. The table below compares all 300 on 8 financial metrics.
| # | Ticker | Company | match | industry_code | industry_group | industry_group_code | Market Capitalization | P/E | P/S | Enterprise Value |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BAIDF | Baidu, Inc. | primary | T-40 | Infrastructure Software | TG-06 | 4.12 Bn | -0.78 | 0.22 | -18.28 Bn |
| 2 | LIF | Life360, Inc. | primary | T-40 | Infrastructure Software | TG-06 | 3.37 Bn | 22.89 | 5.89 | 3.10 Bn |
| 3 | SOUN | Soundhound Ai, Inc. | primary | T-40 | Infrastructure Software | TG-06 | 2.70 Bn | -19.73 | 13.31 | 2.50 Bn |
| 4 | AI | C3.ai, Inc. | primary | T-40 | Infrastructure Software | TG-06 | 1.47 Bn | -3.13 | 5.88 | 0.90 Bn |
| 5 | FCCN | SPECTRAL CAPITAL Corp | primary | T-40 | Infrastructure Software | TG-06 | 0.46 Bn | 1,025.10 | 0.68 | 0.45 Bn |
| 6 | SPIR | Spire Global, Inc. | primary | T-40 | Infrastructure Software | TG-06 | 0.43 Bn | 7.91 | 6.56 | 0.34 Bn |
| 7 | GLAI | Global AI, Inc. | primary | T-40 | Infrastructure Software | TG-06 | 0.15 Bn | -136.56 | 798.54 | 0.15 Bn |
| 8 | VERI | Veritone, Inc. | primary | T-40 | Infrastructure Software | TG-06 | 0.08 Bn | -0.73 | 0.88 | 0.07 Bn |
| 9 | AASP | Agassi Sports Entertainment Corp. | primary | T-40 | Infrastructure Software | TG-06 | 0.08 Bn | -5.76 | — | 0.08 Bn |
| 10 | JFU | 9F Inc. | primary | T-40 | Infrastructure Software | TG-06 | 0.06 Bn | 1.25 | 3.11 | 0.07 Bn |
| 11 | MFI | mF International Ltd | primary | T-40 | Infrastructure Software | TG-06 | 0.05 Bn | — | 12.47 | 0.02 Bn |
| 12 | STEM | Stem, Inc. | primary | T-40 | Infrastructure Software | TG-06 | 0.05 Bn | -0.63 | 0.31 | 0.01 Bn |
| 13 | BBAI-WT | BigBear.ai Holdings, Inc. | primary | T-40 | Infrastructure Software | TG-06 | 0.02 Bn | -0.28 | 0.18 | -0.29 Bn |
| 14 | AVAI | Avai Bio, Inc. | primary | T-40 | Infrastructure Software | TG-06 | 0.02 Bn | -8.59 | — | 0.02 Bn |
| 15 | NXNT | Nexscient, Inc. | primary | T-40 | Infrastructure Software | TG-06 | 0.01 Bn | -24.15 | 13.11 | 0.01 Bn |
| 16 | ARAI | Arrive AI Inc. | primary | T-40 | Infrastructure Software | TG-06 | 0.01 Bn | -0.42 | 220.77 | 0.01 Bn |
| 17 | MSAI | MultiSensor AI Holdings, Inc. | primary | T-40 | Infrastructure Software | TG-06 | 0.01 Bn | -1.54 | 1.58 | -0.01 Bn |
| 18 | ONEI | OneMeta Inc. | primary | T-40 | Infrastructure Software | TG-06 | 0.01 Bn | -0.97 | 6.00 | 0.01 Bn |
| 19 | GXAI | Gaxos.Ai Inc. | primary | T-40 | Infrastructure Software | TG-06 | 0.01 Bn | -1.60 | 1.77 | 0.01 Bn |
| 20 | GDLG | Glidelogic Corp. | primary | T-40 | Infrastructure Software | TG-06 | 0.01 Bn | -50.40 | — | 0.01 Bn |
| 21 | QGAI | Quantum Genesis AI Corp. | primary | T-40 | Infrastructure Software | TG-06 | 0.00 Bn | -0.80 | — | 0.00 Bn |
| 22 | EVGN | Evogene Ltd. | primary | T-40 | Infrastructure Software | TG-06 | 0.00 Bn | -0.42 | 2.91 | 0.00 Bn |
| 23 | VRSSF | Verses AI Inc. | primary | T-40 | Infrastructure Software | TG-06 | 0.00 Bn | -0.09 | 4.03 | 0.00 Bn |
| 24 | GRHI | Gold Rock Holdings, Inc. | primary | T-40 | Infrastructure Software | TG-06 | 0.00 Bn | -12.68 | 11.26 | 0.00 Bn |
| 25 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | primary | T-40 | Infrastructure Software | TG-06 | 0.00 Bn | -0.16 | — | 0.00 Bn |
| 26 | FUSEW | Fusemachines Inc. | primary | T-40 | Infrastructure Software | TG-06 | 0.00 Bn | -0.06 | 0.19 | 0.00 Bn |
| 27 | GDC | GD Culture Group Ltd | primary | T-40 | Infrastructure Software | TG-06 | 0.00 Bn | 0.00 | — | 0.00 Bn |
| 28 | FTSP | FinTrade Sherpa, Inc. | primary | T-40 | Infrastructure Software | TG-06 | 0.00 Bn | -3.59 | — | 0.00 Bn |
| 29 | KSEZ | Kinetic Seas Inc. | primary | T-40 | Infrastructure Software | TG-06 | 0.00 Bn | 2.38 | 78.04 | 0.00 Bn |
| 30 | TRSO | Transuite.Org Inc. | primary | T-40 | Infrastructure Software | TG-06 | 0.00 Bn | -0.02 | 3.04 | 0.00 Bn |
| 31 | BNAIW | Brand Engagement Network Inc. | primary | T-40 | Infrastructure Software | TG-06 | 0.00 Bn | — | — | -0.01 Bn |
| 32 | AIXI | Xiao-I Corp | primary | T-40 | Infrastructure Software | TG-06 | 0.00 Bn | 0.00 | 0.00 | 0.00 Bn |
| 33 | IMAA | IMA Tech | primary | T-40 | Infrastructure Software | TG-06 | 0.00 Bn | -1.32 | 0.94 | 0.00 Bn |
| 34 | YYAI | Airwa Inc. | primary | T-40 | Infrastructure Software | TG-06 | 0.00 Bn | 3.45 | 0.00 | -0.04 Bn |
| 35 | OBAI | Our Bond, Inc. | primary | T-40 | Infrastructure Software | TG-06 | 0.00 Bn | 0.00 | 0.00 | 0.00 Bn |
| 36 | NVDA | Nvidia Corp | secondary | T-01 | Semiconductors | TG-01 | 5,284.31 Bn | 27.40 | 17.44 | 5,219.08 Bn |
| 37 | JNJ | Johnson & Johnson | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 641.14 Bn | 30.48 | 6.55 | 620.38 Bn |
| 38 | ABBV | AbbVie Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 451.04 Bn | 71.41 | 7.01 | 444.47 Bn |
| 39 | PLTR | Palantir Technologies Inc. | secondary | T-23 | Business Applications | TG-03 | 398.27 Bn | 131.41 | 64.70 | 388.87 Bn |
| 40 | MRK | Merck & Co., Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 357.43 Bn | 112.79 | 5.37 | 350.29 Bn |
| 41 | IBM | International Business Machines Corp | secondary | T-43 | Cloud Computing | TG-07 | 220.30 Bn | 20.54 | 3.19 | 208.94 Bn |
| 42 | AMGN | Amgen Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 206.44 Bn | 23.61 | 5.42 | 192.45 Bn |
| 43 | CRM | Salesforce, Inc. | secondary | T-16 | Business Applications | TG-03 | 199.60 Bn | 20.63 | 4.54 | 188.20 Bn |
| 44 | GILD | Gilead Sciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 179.97 Bn | -62.17 | 5.91 | 176.79 Bn |
| 45 | VRTX | Vertex Pharmaceuticals Inc / Ma | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 130.57 Bn | 29.64 | 10.37 | 122.72 Bn |
| 46 | SNOW | Snowflake Inc. | secondary | T-36 | Infrastructure Software | TG-06 | 114.92 Bn | -105.58 | 21.15 | 112.57 Bn |
| 47 | NET | Cloudflare, Inc. | secondary | T-45 | Cloud Computing | TG-07 | 110.37 Bn | -535.10 | 43.93 | 106.21 Bn |
| 48 | ADBE | Adobe Inc. | secondary | T-25 | Workplace Software | TG-04 | 99.95 Bn | 13.83 | 3.97 | 94.32 Bn |
| 49 | SLB | Slb Limited/Nv | secondary | E-10 | Oilfield Services and Equipment | EG-04 | 83.41 Bn | 28.38 | 2.97 | 79.34 Bn |
| 50 | REGN | Regeneron Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 81.63 Bn | 18.86 | 5.25 | 73.63 Bn |
| 51 | MSI | Motorola Solutions, Inc. | secondary | I-02 | Aerospace and Defense | IG-01 | 76.80 Bn | 35.89 | 6.28 | 76.09 Bn |
| 52 | ARGX | Argenx Se | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 60.34 Bn | 35.18 | 11.55 | 55.16 Bn |
| 53 | NBIS | Nebius Group N.V. | secondary | T-43 | Cloud Computing | TG-07 | 55.32 Bn | -216.11 | 40.82 | 47.28 Bn |
| 54 | MRNA | Moderna, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 54.37 Bn | -17.25 | 24.40 | 49.23 Bn |
| 55 | SNY | Sanofi | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 52.14 Bn | 11.19 | 0.97 | 44.76 Bn |
| 56 | CRWV | CoreWeave, Inc. | secondary | T-43 | Cloud Computing | TG-07 | 49.07 Bn | -25.45 | 6.47 | 43.54 Bn |
| 57 | TEVA | Teva Pharmaceutical Industries Ltd | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 42.33 Bn | 60.82 | 2.44 | 38.68 Bn |
| 58 | ALNY | Alnylam Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 33.07 Bn | 42.69 | 6.88 | 29.76 Bn |
| 59 | BIIB | Biogen Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 31.84 Bn | 38.15 | 3.17 | 30.55 Bn |
| 60 | ROIV | Roivant Sciences Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 29.49 Bn | -19.87 | 2,700.12 | 29.49 Bn |
| 61 | INSM | INSMED Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 27.67 Bn | -31.61 | 24.33 | 26.51 Bn |
| 62 | INCY | Incyte Corp | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 24.70 Bn | 15.32 | 4.24 | 20.16 Bn |
| 63 | BNTX | BioNTech SE | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 23.29 Bn | -13.66 | 7.53 | 9.63 Bn |
| 64 | IOT | Samsara Inc. | secondary | T-32 | Vertical Software | TG-05 | 22.46 Bn | 248.03 | 12.16 | 21.63 Bn |
| 65 | RBRK | Rubrik, Inc. | secondary | T-38 | Infrastructure Software | TG-06 | 18.39 Bn | -72.26 | 11.92 | 16.64 Bn |
| 66 | ZBH | Zimmer Biomet Holdings, Inc. | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 17.73 Bn | 20.93 | 2.08 | 17.32 Bn |
| 67 | NTNX | Nutanix, Inc. | secondary | T-43 | Cloud Computing | TG-07 | 17.40 Bn | 68.32 | 6.33 | 15.38 Bn |
| 68 | ASND | Ascendis Pharma A/S | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 15.83 Bn | 18.25 | 11.16 | 14.88 Bn |
| 69 | NBIX | Neurocrine Biosciences Inc | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 15.82 Bn | 22.42 | 4.69 | 15.43 Bn |
| 70 | MDGL | Madrigal Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 15.52 Bn | -48.66 | 12.09 | 14.68 Bn |
| 71 | JAZZ | Jazz Pharmaceuticals plc | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 15.21 Bn | 16.17 | 3.31 | 13.59 Bn |
| 72 | EXEL | Exelixis, Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 14.39 Bn | 16.72 | 5.91 | 13.55 Bn |
| 73 | BBIO | BridgeBio Pharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 14.19 Bn | -20.51 | 19.90 | 13.47 Bn |
| 74 | CHKP | Check Point Software Technologies Ltd | secondary | T-38 | Infrastructure Software | TG-06 | 13.98 Bn | 13.33 | 5.06 | 11.70 Bn |
| 75 | DOCN | DigitalOcean Holdings, Inc. | secondary | T-43 | Cloud Computing | TG-07 | 13.69 Bn | 58.18 | 13.53 | 12.92 Bn |
| 76 | SMMT | Summit Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 13.23 Bn | — | — | 12.54 Bn |
| 77 | BMRN | Biomarin Pharmaceutical Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.67 Bn | 173.64 | 3.72 | 11.80 Bn |
| 78 | HALO | Halozyme Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.55 Bn | 30.34 | 7.54 | 12.32 Bn |
| 79 | ARWR | Arrowhead Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 11.87 Bn | -43.61 | 17.73 | 10.27 Bn |
| 80 | AXSM | Axsome Therapeutics, Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 10.94 Bn | -71.14 | 14.08 | 10.62 Bn |
| 81 | AAVXF | Abivax S.A. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.92 Bn | -25.97 | — | 10.92 Bn |
| 82 | FROG | JFrog Ltd | secondary | T-34 | Infrastructure Software | TG-06 | 10.78 Bn | -200.56 | 17.97 | 9.96 Bn |
| 83 | APGE | Apogee Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.18 Bn | -34.62 | — | 9.20 Bn |
| 84 | GMED | Globus Medical Inc | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 9.94 Bn | 18.57 | 3.16 | 9.35 Bn |
| 85 | PRAX | Praxis Precision Medicines, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.87 Bn | -25.87 | — | 9.11 Bn |
| 86 | RDY | Dr Reddys Laboratories Ltd | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 9.76 Bn | 773.25 | 2.66 | 9.58 Bn |
| 87 | PTGX | Protagonist Therapeutics, Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.56 Bn | 86.56 | 33.90 | 9.56 Bn |
| 88 | SNAP | Snap Inc | secondary | T-47 | Internet Platforms | TG-08 | 9.22 Bn | -29.63 | 1.45 | 6.56 Bn |
| 89 | IONS | Ionis Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.21 Bn | -43.38 | 10.53 | 7.15 Bn |
| 90 | GPCR | Structure Therapeutics Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 8.62 Bn | -45.80 | — | 8.62 Bn |
| 91 | PCVX | Vaxcyte, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.51 Bn | -8.05 | — | 8.51 Bn |
| 92 | IBRX | ImmunityBio, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.10 Bn | -8.16 | 48.86 | 7.74 Bn |
| 93 | GTLB | Gitlab Inc. | secondary | T-34 | Infrastructure Software | TG-06 | 7.98 Bn | -147.82 | 7.56 | 6.72 Bn |
| 94 | TGTX | Tg Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.84 Bn | 17.74 | 9.80 | 7.16 Bn |
| 95 | IMVT | Immunovant, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.82 Bn | -14.52 | — | 7.82 Bn |
| 96 | GIFLF | Grifols SA | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.54 Bn | 29.70 | 0.46 | 9.09 Bn |
| 97 | SYRE | Spyre Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.49 Bn | -41.86 | — | 7.49 Bn |
| 98 | BZ | Kanzhun Ltd | secondary | T-21 | Business Applications | TG-03 | 7.41 Bn | 11.11 | 5.91 | 5.10 Bn |
| 99 | SRRK | Scholar Rock Holding Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.25 Bn | -17.96 | — | 7.25 Bn |
| 100 | PATH | UiPath, Inc. | secondary | T-20 | Business Applications | TG-03 | 7.21 Bn | 19.93 | 4.19 | 5.93 Bn |
| 101 | RYTM | Rhythm Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.01 Bn | -33.34 | 29.22 | 6.68 Bn |
| 102 | S | SentinelOne, Inc. | secondary | T-38 | Infrastructure Software | TG-06 | 6.78 Bn | -19.92 | 6.17 | 6.12 Bn |
| 103 | MIRM | Mirum Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.38 Bn | -7.41 | 10.32 | 5.94 Bn |
| 104 | CGON | CG Oncology, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.34 Bn | -28.31 | 1,018.73 | 6.34 Bn |
| 105 | BLRX | BioLineRx Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.33 Bn | -707.29 | 4,550.66 | 6.33 Bn |
| 106 | NTSK | Netskope Inc | secondary | T-38 | Infrastructure Software | TG-06 | 6.11 Bn | -10.44 | 7.62 | 5.04 Bn |
| 107 | KNSA | Kiniksa Pharmaceuticals International, plc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.93 Bn | 73.54 | 7.05 | 5.41 Bn |
| 108 | PEGA | Pegasystems Inc | secondary | T-20 | Business Applications | TG-03 | 5.92 Bn | 18.28 | 3.41 | 5.92 Bn |
| 109 | XENE | Xenon Pharmaceuticals Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.86 Bn | -16.17 | — | 5.86 Bn |
| 110 | COGT | Cogent Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.83 Bn | -15.77 | — | 5.83 Bn |
| 111 | G | Genpact LTD | secondary | I-26 | Business Services | IG-06 | 5.81 Bn | 9.97 | 1.11 | 5.29 Bn |
| 112 | LGND | Ligand Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.80 Bn | 29.43 | 19.98 | 4.45 Bn |
| 113 | ORKA | Oruka Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.77 Bn | — | — | 4.04 Bn |
| 114 | DBVT | DBV Technologies S.A. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.62 Bn | -31.93 | 1,119.47 | 5.44 Bn |
| 115 | PTCT | Ptc Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.59 Bn | 14.62 | 5.54 | 3.36 Bn |
| 116 | SOGP | Sound Group Inc. | secondary | T-47 | Internet Platforms | TG-08 | 5.58 Bn | -301.32 | 8.10 | 5.48 Bn |
| 117 | NAVN | Navan, Inc. | secondary | T-18 | Business Applications | TG-03 | 5.08 Bn | -13.36 | 6.76 | 4.40 Bn |
| 118 | ERAS | Erasca, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.97 Bn | -17.31 | — | 4.97 Bn |
| 119 | CELC | Celcuity Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.68 Bn | -21.39 | — | 4.68 Bn |
| 120 | ITRI | Itron, Inc. | secondary | I-07 | Machinery | IG-02 | 4.12 Bn | 13.83 | 1.79 | 3.38 Bn |
| 121 | DNLI | Denali Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.01 Bn | -7.84 | 1,112.24 | 4.01 Bn |
| 122 | DNTH | Dianthus Therapeutics, Inc. /DE/ | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.91 Bn | — | — | 3.51 Bn |
| 123 | TLPPF | Telix Pharmaceuticals Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.89 Bn | -521.64 | 4.64 | 3.59 Bn |
| 124 | RLAY | Relay Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.84 Bn | -13.44 | 371.20 | 3.84 Bn |
| 125 | VKTX | Viking Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.74 Bn | -6.99 | — | 3.74 Bn |
| 126 | IOVA | Iovance Biotherapeutics, Inc. | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 3.65 Bn | -17.48 | 11.24 | 3.36 Bn |
| 127 | AMLX | Amylyx Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.57 Bn | -29.39 | — | 3.57 Bn |
| 128 | TNGX | Tango Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.50 Bn | -34.24 | 65.12 | 2.49 Bn |
| 129 | IDYA | IDEAYA Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.45 Bn | -15.66 | 14.72 | 2.62 Bn |
| 130 | FLY | Firefly Aerospace Inc. | secondary | I-03 | Aerospace and Defense | IG-01 | 3.37 Bn | -9.11 | 11.76 | 2.56 Bn |
| 131 | RCUS | Arcus Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.27 Bn | -7.11 | 27.96 | 2.57 Bn |
| 132 | ABCL | AbCellera Biologics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.19 Bn | -19.40 | 48.28 | 3.19 Bn |
| 133 | ARQT | Arcutis Biotherapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.05 Bn | 107.18 | 6.58 | 2.82 Bn |
| 134 | DYN | Dyne Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.04 Bn | -5.89 | — | 3.04 Bn |
| 135 | AMBA | Ambarella Inc | secondary | T-01 | Semiconductors | TG-01 | 2.98 Bn | -52.77 | 7.14 | 2.71 Bn |
| 136 | CLDX | Celldex Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.96 Bn | -9.64 | 18,760.43 | 2.96 Bn |
| 137 | MBX | MBX Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.90 Bn | -27.84 | — | 2.90 Bn |
| 138 | NRIX | Nurix Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.87 Bn | -8.41 | 78.07 | 2.43 Bn |
| 139 | IRON | Disc Medicine, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.87 Bn | -14.24 | — | 2.87 Bn |
| 140 | IMNM | Immunome Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.83 Bn | -10.46 | 593.06 | 2.31 Bn |
| 141 | KC | Kingsoft Cloud Holdings Ltd | secondary | T-43 | Cloud Computing | TG-07 | 2.71 Bn | -31.59 | 1.71 | 2.02 Bn |
| 142 | ZLAB | Zai Lab Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.69 Bn | -14.30 | 5.98 | 1.98 Bn |
| 143 | TAK | Takeda Pharmaceutical Co Ltd | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.59 Bn | 4.52 | 0.06 | -3.20 Bn |
| 144 | COHU | Cohu Inc | secondary | T-03 | Semiconductors | TG-01 | 2.59 Bn | -35.27 | 4.96 | 2.09 Bn |
| 145 | TDC | Teradata Corp /De/ | secondary | T-36 | Infrastructure Software | TG-06 | 2.57 Bn | 5.61 | 1.52 | 2.16 Bn |
| 146 | SLS | SELLAS Life Sciences Group, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.55 Bn | -78.59 | — | 2.55 Bn |
| 147 | BEIGF | BeOne Medicines Ltd. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.48 Bn | 3.74 | 0.40 | -2.62 Bn |
| 148 | UPST | Upstart Holdings, Inc. | secondary | T-56 | Fintech | TG-09 | 2.43 Bn | 40.22 | 1.95 | 1.97 Bn |
| 149 | SUPN | Supernus Pharmaceuticals, Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.42 Bn | -28.47 | 3.07 | 2.05 Bn |
| 150 | VERA | Vera Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.42 Bn | -6.03 | — | 2.42 Bn |
| 151 | OCUL | Ocular Therapeutix, Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.39 Bn | -7.90 | 45.94 | 2.39 Bn |
| 152 | XTLB | Xtl Biopharmaceuticals Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.38 Bn | -2,975.41 | — | 2.38 Bn |
| 153 | HRMY | Harmony Biosciences Holdings, Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.38 Bn | 13.34 | 2.48 | 1.57 Bn |
| 154 | NKTR | Nektar Therapeutics | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.34 Bn | -19.72 | 42.93 | 1.66 Bn |
| 155 | VRDN | Viridian Therapeutics, Inc.\DE | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.34 Bn | -5.84 | 32.87 | 2.34 Bn |
| 156 | AXGN | Axogen, Inc. | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 2.24 Bn | -151.28 | 8.91 | 2.13 Bn |
| 157 | PHVS | Pharvaris N.V. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.23 Bn | -11.21 | — | 1.86 Bn |
| 158 | NUVB | Nuvation Bio Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.20 Bn | -20.32 | 12.93 | 2.20 Bn |
| 159 | SRPT | Sarepta Therapeutics, Inc. | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 2.16 Bn | -15.77 | 1.10 | 1.37 Bn |
| 160 | ADMA | Adma Biologics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.14 Bn | 12.88 | 4.18 | 2.01 Bn |
| 161 | URGN | UroGen Pharma Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.13 Bn | -34.18 | 11.28 | 2.02 Bn |
| 162 | BCRX | Biocryst Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.11 Bn | -5.47 | 3.94 | 1.75 Bn |
| 163 | AUPH | Aurinia Pharmaceuticals Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.09 Bn | 6.67 | 6.72 | 1.65 Bn |
| 164 | GMAB | Genmab A/S | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.09 Bn | 0.17 | 0.33 | 0.58 Bn |
| 165 | RAPP | Rapport Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.07 Bn | -15.06 | 103.30 | 2.07 Bn |
| 166 | KOD | Kodiak Sciences Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.06 Bn | -8.50 | — | 2.06 Bn |
| 167 | AGIO | Agios Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.99 Bn | -4.84 | 20.26 | 1.99 Bn |
| 168 | ZBIO | Zenas BioPharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.95 Bn | -4.68 | 1,945.12 | 1.95 Bn |
| 169 | STOK | Stoke Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.94 Bn | -9.33 | 70.26 | 1.65 Bn |
| 170 | ZYME | Zymeworks Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.93 Bn | -12.89 | 52.06 | 1.66 Bn |
| 171 | BHVN | Biohaven Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.92 Bn | -3.28 | — | 1.66 Bn |
| 172 | CMPS | COMPASS Pathways plc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.92 Bn | -4.87 | — | 1.92 Bn |
| 173 | XNCR | Xencor Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.84 Bn | -11.27 | 17.54 | 1.46 Bn |
| 174 | VIR | Vir Biotechnology, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.77 Bn | -7.05 | 5.85 | 1.77 Bn |
| 175 | QUBT | Quantum Computing Inc. | secondary | T-42 | Infrastructure Software | TG-06 | 1.76 Bn | -117.34 | 178.88 | 1.76 Bn |
| 176 | INBX | Inhibrx Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.75 Bn | -13.10 | 1,344.64 | 1.75 Bn |
| 177 | DAO | Youdao, Inc. | secondary | T-28 | Vertical Software | TG-05 | 1.75 Bn | 70.83 | 2.02 | 1.62 Bn |
| 178 | GLPGF | Lakefront Biotherapeutics NV | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.73 Bn | 0.00 | 1.50 | 1.73 Bn |
| 179 | IMCR | Immunocore Holdings plc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.71 Bn | -94.63 | 3.98 | 0.83 Bn |
| 180 | SEPN | Septerna, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.70 Bn | -121.81 | 17.20 | 1.70 Bn |
| 181 | RXRX | Recursion Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.69 Bn | -3.25 | 30.72 | 1.13 Bn |
| 182 | SNDX | Syndax Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.67 Bn | -9.22 | 6.62 | 1.12 Bn |
| 183 | GHRS | GH Research PLC | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.66 Bn | -26.69 | — | 1.30 Bn |
| 184 | DMRA | Damora Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.65 Bn | -6.28 | — | 1.11 Bn |
| 185 | GLOB | Globant S.A. | secondary | T-63 | Technology Services | TG-11 | 1.62 Bn | 14.33 | 0.66 | 1.45 Bn |
| 186 | OPRA | Opera Ltd | secondary | T-33 | Infrastructure Software | TG-06 | 1.62 Bn | 12.78 | 2.37 | 1.47 Bn |
| 187 | AMPL | Amplitude, Inc. | secondary | T-23 | Business Applications | TG-03 | 1.61 Bn | -18.86 | 4.30 | 1.43 Bn |
| 188 | ATAI | AtaiBeckley Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.60 Bn | -10.40 | 527.33 | 1.60 Bn |
| 189 | ANAB | Anaptysbio, Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.58 Bn | -66.19 | 7.94 | 1.29 Bn |
| 190 | FBRX | Forte Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.58 Bn | -20.71 | — | 1.23 Bn |
| 191 | BCAX | Bicara Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.57 Bn | -8.46 | — | 1.57 Bn |
| 192 | TYRA | Tyra Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.56 Bn | -10.48 | — | 1.56 Bn |
| 193 | NVAX | Novavax Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.53 Bn | -6.19 | 3.70 | 0.81 Bn |
| 194 | SCNI | Scinai Immunotherapeutics Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.52 Bn | -181.75 | 884.05 | 1.52 Bn |
| 195 | AAPG | Ascentage Pharma Group International | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.49 Bn | -9.11 | 20.12 | 1.21 Bn |
| 196 | RARE | Ultragenyx Pharmaceutical Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.47 Bn | -3.18 | 2.05 | 1.18 Bn |
| 197 | MAZE | Maze Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.47 Bn | -13.85 | 73.44 | 1.47 Bn |
| 198 | GLUE | Monte Rosa Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.45 Bn | -9.43 | 50.55 | 0.82 Bn |
| 199 | SDGR | Schrodinger, Inc. | secondary | T-27 | Vertical Software | TG-05 | 1.40 Bn | -25.79 | 5.41 | 0.99 Bn |
| 200 | AVBP | ArriVent BioPharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.37 Bn | -8.37 | — | 1.37 Bn |
| 201 | ANRO | Alto Neuroscience, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.36 Bn | -16.21 | — | 1.36 Bn |
| 202 | SVRA | Savara Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.35 Bn | -9.67 | — | 1.35 Bn |
| 203 | OMER | Omeros Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.34 Bn | 78.67 | 34.95 | 1.34 Bn |
| 204 | FLNC | Fluence Energy, Inc. | secondary | I-43 | Clean Energy Equipment | IG-10 | 1.34 Bn | -12.87 | 0.51 | 0.77 Bn |
| 205 | ORIC | Oric Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.30 Bn | -8.28 | — | 1.30 Bn |
| 206 | CGEM | Cullinan Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.30 Bn | -6.37 | — | 1.30 Bn |
| 207 | ABSI | Absci Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.30 Bn | -10.72 | 831.75 | 1.10 Bn |
| 208 | REPL | Replimune Group, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.28 Bn | -4.32 | — | 1.28 Bn |
| 209 | ALMS | Alumis Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.27 Bn | -5.24 | 152.36 | 0.77 Bn |
| 210 | VOR | Vor Biopharma Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.21 Bn | -1.32 | — | 1.21 Bn |
| 211 | CRVS | Corvus Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.19 Bn | -24.95 | — | 0.98 Bn |
| 212 | MNKD | Mannkind Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.17 Bn | -26.90 | 2.98 | 1.06 Bn |
| 213 | JBIO | Jade Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.17 Bn | -7.61 | — | 1.17 Bn |
| 214 | YELP | Yelp Inc | secondary | T-47 | Internet Platforms | TG-08 | 1.16 Bn | 9.15 | 0.79 | 1.06 Bn |
| 215 | CLYM | Climb Bio, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.13 Bn | -19.65 | — | 1.13 Bn |
| 216 | JANX | Janux Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.11 Bn | -10.85 | 46.36 | 1.11 Bn |
| 217 | IMTX | Immatics N.V. | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 1.07 Bn | -4.45 | 22.07 | 0.62 Bn |
| 218 | PD | PagerDuty, Inc. | secondary | T-37 | Infrastructure Software | TG-06 | 1.07 Bn | 5.75 | 2.15 | 0.60 Bn |
| 219 | ABUS | Arbutus Biopharma Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.01 Bn | 6.64 | 5.57 | 0.92 Bn |
| 220 | OKYO | OKYO Pharma Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.98 Bn | -118.02 | — | 0.98 Bn |
| 221 | MLTX | MoonLake Immunotherapeutics | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.97 Bn | -3.67 | — | 0.44 Bn |
| 222 | WVE | Wave Life Sciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.95 Bn | -4.70 | 14.54 | 0.58 Bn |
| 223 | MNPR | Monopar Therapeutics | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.94 Bn | -67.71 | — | 0.89 Bn |
| 224 | GERN | Geron Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.91 Bn | -13.59 | 3.75 | 0.61 Bn |
| 225 | ARDX | Ardelyx, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.90 Bn | -16.10 | 1.99 | 0.61 Bn |
| 226 | TBPH | Theravance Biopharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.88 Bn | 20.81 | 8.44 | 0.49 Bn |
| 227 | RIGL | Rigel Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.88 Bn | 2.72 | 3.16 | 0.78 Bn |
| 228 | CRTO | Criteo S.A. | secondary | T-50 | Internet Platforms | TG-08 | 0.86 Bn | 10.34 | 0.48 | 0.58 Bn |
| 229 | FINV | FinVolution Group | secondary | T-56 | Fintech | TG-09 | 0.86 Bn | 2.76 | 0.45 | -0.09 Bn |
| 230 | ANNX | Annexon, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.83 Bn | -4.06 | — | 0.83 Bn |
| 231 | STTK | Shattuck Labs, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.80 Bn | -14.79 | 798.14 | 0.80 Bn |
| 232 | ACRS | Aclaris Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.79 Bn | -9.87 | 95.55 | 0.79 Bn |
| 233 | CEVA | Ceva Inc | secondary | T-05 | Semiconductors | TG-01 | 0.78 Bn | -302.51 | — | 0.78 Bn |
| 234 | VSTM | Verastem, Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.76 Bn | -6.63 | 8.73 | 0.63 Bn |
| 235 | AVTX | Avalo Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.75 Bn | -7.46 | — | 0.75 Bn |
| 236 | PUBM | PubMatic, Inc. | secondary | T-50 | Internet Platforms | TG-08 | 0.75 Bn | -55.44 | 2.59 | 0.61 Bn |
| 237 | PHAR | Pharming Group N.V. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.74 Bn | -120.02 | 2.24 | 0.58 Bn |
| 238 | CTMX | CytomX Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.73 Bn | -9.69 | 40.13 | 0.40 Bn |
| 239 | ZVRA | Zevra Therapeutics, Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.71 Bn | 12.26 | 5.25 | 0.49 Bn |
| 240 | ZURA | Zura Bio Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.68 Bn | -5.87 | — | 0.68 Bn |
| 241 | AURA | Aura Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.66 Bn | -6.06 | — | 0.60 Bn |
| 242 | IRWD | Ironwood Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.65 Bn | 2.95 | 1.68 | 0.57 Bn |
| 243 | SLN | Silence Therapeutics plc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.63 Bn | -16.17 | 1,021.92 | 0.56 Bn |
| 244 | CRMD | CorMedix Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.62 Bn | 4.96 | 1.67 | 0.37 Bn |
| 245 | ALT | Altimmune, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.61 Bn | -8.26 | — | 0.61 Bn |
| 246 | CBIO | Crescent Biopharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.60 Bn | -3.69 | 579.05 | 0.43 Bn |
| 247 | OCS | Oculis Holding AG | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.59 Bn | -338,119.55 | — | 0.59 Bn |
| 248 | SGMT | Sagimet Biosciences Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.59 Bn | -12.17 | — | 0.59 Bn |
| 249 | ASMB | Assembly Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.57 Bn | 461.94 | 7.68 | 0.25 Bn |
| 250 | ARVN | Arvinas, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.56 Bn | 60.69 | 1.78 | 0.00 Bn |
| 251 | VALN | Valneva SE | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.56 Bn | -9.68 | 3.39 | 0.42 Bn |
| 252 | FLGT | Fulgent Genetics, Inc. | secondary | H-17 | Healthcare Providers | HG-04 | 0.56 Bn | -6.67 | 2.34 | 0.31 Bn |
| 253 | CTNM | Contineum Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.55 Bn | -9.08 | — | 0.55 Bn |
| 254 | TECX | Tectonic Therapeutic, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.54 Bn | -6.34 | — | 0.54 Bn |
| 255 | XMAX | XMax Inc. | secondary | D-07 | Household Durables | DG-02 | 0.52 Bn | 17.44 | 32.42 | 0.48 Bn |
| 256 | OVID | Ovid Therapeutics Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.52 Bn | -15.08 | 328.67 | 0.40 Bn |
| 257 | SOPH | SOPHiA GENETICS SA | secondary | T-27 | Vertical Software | TG-05 | 0.51 Bn | -6.35 | 5.96 | 0.41 Bn |
| 258 | OABI | OmniAb, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.51 Bn | -11.48 | 13.21 | 0.46 Bn |
| 259 | IMUX | Immunic, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.50 Bn | -4.35 | — | 0.50 Bn |
| 260 | ANL | Adlai Nortye Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.49 Bn | -10.27 | 78.36 | 0.26 Bn |
| 261 | PRTA | Prothena Corp Public Ltd Co | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.47 Bn | -10.66 | 8.59 | 0.18 Bn |
| 262 | PBYI | Puma Biotechnology, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.47 Bn | 15.56 | 2.02 | 0.37 Bn |
| 263 | CNTN | Canton Strategic Holdings, Inc. | secondary | T-58 | Fintech | TG-09 | 0.47 Bn | -5.65 | 330.55 | 0.47 Bn |
| 264 | NEUP | Neuphoria Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.46 Bn | -19.56 | — | 0.44 Bn |
| 265 | KMDA | Kamada Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.46 Bn | 14.81 | 2.40 | 0.39 Bn |
| 266 | PRLD | Prelude Therapeutics Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.46 Bn | -6.80 | 20.42 | 0.18 Bn |
| 267 | RLMD | Relmada Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.46 Bn | -7.48 | — | 0.46 Bn |
| 268 | DRUG | Bright Minds Biosciences Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.45 Bn | -15.37 | — | 0.45 Bn |
| 269 | CCCC | C4 Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.45 Bn | -4.40 | 12.72 | 0.19 Bn |
| 270 | BBOT | BridgeBio Oncology Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.44 Bn | -2.23 | — | 0.22 Bn |
| 271 | RZLT | Rezolute, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.43 Bn | -5.32 | — | 0.43 Bn |
| 272 | RMNI | Rimini Street, Inc. | secondary | T-63 | Technology Services | TG-11 | 0.43 Bn | 58.71 | 0.99 | 0.30 Bn |
| 273 | AVIR | Atea Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.42 Bn | -3.04 | — | 0.42 Bn |
| 274 | CYPH | Cypherpunk Technologies Inc. | secondary | T-58 | Fintech | TG-09 | 0.41 Bn | 6.81 | — | 0.41 Bn |
| 275 | LRMR | Larimar Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.40 Bn | -2.27 | — | 0.24 Bn |
| 276 | ARCT | Arcturus Therapeutics Holdings Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.40 Bn | -4.19 | 13.57 | 0.21 Bn |
| 277 | BIOA | BioAge Labs, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.39 Bn | -4.12 | 37.37 | 0.39 Bn |
| 278 | CMPX | Compass Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.38 Bn | -4.68 | — | 0.38 Bn |
| 279 | EVMN | Evommune, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.38 Bn | -3.99 | 37.80 | 0.18 Bn |
| 280 | HMDCF | HUTCHMED (China) Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.38 Bn | — | — | 0.39 Bn |
| 281 | RZLV | Rezolve Ai Plc | secondary | T-52 | Internet Platforms | TG-08 | 0.37 Bn | -2.63 | 7.69 | 0.26 Bn |
| 282 | API | Agora, Inc. | secondary | T-26 | Workplace Software | TG-04 | 0.37 Bn | 34.09 | 2.46 | 0.30 Bn |
| 283 | ENTA | Enanta Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.37 Bn | -5.85 | 5.66 | 0.18 Bn |
| 284 | CRNC | Cerence Inc. | secondary | T-35 | Infrastructure Software | TG-06 | 0.37 Bn | -23.92 | 1.19 | 0.24 Bn |
| 285 | EYPT | EyePoint, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.37 Bn | -1.19 | 131.41 | 0.19 Bn |
| 286 | RR | Richtech Robotics Inc. | secondary | T-61 | Robotics and Automation | TG-10 | 0.36 Bn | -12.66 | 67.64 | 0.36 Bn |
| 287 | OFIX | Orthofix Medical Inc. | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 0.36 Bn | -8.13 | 0.43 | 0.25 Bn |
| 288 | DMAC | DiaMedica Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.35 Bn | -10.63 | — | 0.35 Bn |
| 289 | OCGN | Ocugen, Inc. | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.35 Bn | -4.24 | 75.80 | 0.25 Bn |
| 290 | BSAI | Blusky Ai Inc. | secondary | T-44 | Cloud Computing | TG-07 | 0.34 Bn | -24.56 | — | 0.34 Bn |
| 291 | WHWK | Whitehawk Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.34 Bn | -4.22 | — | 0.34 Bn |
| 292 | CATX | Perspective Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.34 Bn | -2.80 | — | 0.34 Bn |
| 293 | EPRX | Eupraxia Pharmaceuticals Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.32 Bn | -6.41 | — | 0.32 Bn |
| 294 | FHTX | Foghorn Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.32 Bn | -4.81 | 8.60 | 0.25 Bn |
| 295 | ELDN | Eledon Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.32 Bn | -3.80 | — | 0.32 Bn |
| 296 | CLLS | Cellectis S.A. | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.31 Bn | -7.54 | 5.31 | 0.15 Bn |
| 297 | UPB | Upstream Bio, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.31 Bn | -1.95 | 99.01 | 0.31 Bn |
| 298 | STRO | Sutro Biopharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.29 Bn | -2.59 | 3.27 | 0.13 Bn |
| 299 | AGEN | Agenus Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | 3.10 | 2.14 | 0.28 Bn |
| 300 | PLTS | Platinum Analytics Cayman Ltd | secondary | T-63 | Technology Services | TG-11 | 0.28 Bn | -164.81 | 165.15 | 0.27 Bn |